Literature DB >> 18690999

Skeletal effects of central nervous system active drugs: anxiolytics, sedatives, antidepressants, lithium and neuroleptics.

Peter Vestergaard1.   

Abstract

Many central nervous system active drugs can alter postural balance, increasing the risk of fractures. Anxiolytics and sedatives include the benzodiazepines, and these have been associated with a limited increase in the risk of fractures, even at low doses, probably from an increased risk of falls. No systematic differences have been shown between benzodiazepines with long and short half-lives. Although the increase in risk of fractures was limited, care must still be taken when prescribing for older fall-prone subjects at risk of osteoporosis. Neuroleptics may be associated with a decrease in bone mineral density and a very limited increase in fracture risk. Antidepressants are associated with a dose-dependent increase in the risk of fractures. The increase in relative risk of fractures seems to be larger with selective serotonin reuptake inhibitors (SSRIs) than with tricyclic antidepressants. The reason for this is not known but may be linked to serotonin effects on bone cells and the risk of falls. With the wide use of SSRIs, more research is needed. Lithium is associated with a decrease in the risk of fractures. This may be linked to its effects on the Wnt glycoprotein family, which is a specialised signalling system for certain cell types.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18690999     DOI: 10.2174/157488608785699432

Source DB:  PubMed          Journal:  Curr Drug Saf        ISSN: 1574-8863


  9 in total

Review 1.  Update in new anabolic therapies for osteoporosis.

Authors:  Ernesto Canalis
Journal:  J Clin Endocrinol Metab       Date:  2010-04       Impact factor: 5.958

2.  The impact of depression on dual tasking among patients with high fall risk.

Authors:  Sara L Wright; Rachel E Kay; Erich T Avery; Bruno Giordani; Neil B Alexander
Journal:  J Geriatr Psychiatry Neurol       Date:  2011-06-24       Impact factor: 2.680

Review 3.  Psychotropic drug-induced falls in older people: a review of interventions aimed at reducing the problem.

Authors:  Keith D Hill; Rohan Wee
Journal:  Drugs Aging       Date:  2012-01-01       Impact factor: 3.923

4.  Affective Disorders, Bone Metabolism, and Osteoporosis.

Authors:  Briana Mezuk
Journal:  Clin Rev Bone Miner Metab       Date:  2008-12

5.  Psychotropic drugs have contrasting skeletal effects that are independent of their effects on physical activity levels.

Authors:  Stuart J Warden; Sean M Hassett; Julie L Bond; Johanna Rydberg; Jamie D Grogg; Erin L Hilles; Elizabeth D Bogenschutz; Heather D Smith; Robyn K Fuchs; M Michael Bliziotes; Charles H Turner
Journal:  Bone       Date:  2010-01-06       Impact factor: 4.398

6.  Derivatives of a new heterocyclic system - pyrano[3,4-c][1,2,4]triazolo[4,3-a]pyridines: synthesis, docking analysis and neurotropic activity.

Authors:  Ervand G Paronikyan; Anthi Petrou; Maria Fesatidou; Athina Geronikaki; Shushanik Sh Dashyan; Suren S Mamyan; Ruzanna G Paronikyan; Ivetta M Nazaryan; Hasmik H Hakopyan
Journal:  Medchemcomm       Date:  2019-06-19       Impact factor: 3.597

Review 7.  WNT Signaling and Bone: Lessons From Skeletal Dysplasias and Disorders.

Authors:  Yentl Huybrechts; Geert Mortier; Eveline Boudin; Wim Van Hul
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-09       Impact factor: 5.555

8.  Self-reported Sleep Quality and Bone Outcomes in Older Adults: Findings from the Hertfordshire Cohort Study.

Authors:  Gregorio Bevilacqua; Hayley J Denison; Faidra Laskou; Karen A Jameson; Kate A Ward; Cyrus Cooper; Elaine M Dennison
Journal:  Calcif Tissue Int       Date:  2020-01-18       Impact factor: 4.333

9.  Predictors of falls and fractures leading to hospitalisation in 36 101 people with affective disorders: a large representative cohort study.

Authors:  Ruimin Ma; Gayan Perera; Eugenia Romano; Davy Vancampfort; Ai Koyanagi; Robert Stewart; Christoph Mueller; Brendon Stubbs
Journal:  BMJ Open       Date:  2022-03-11       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.